XCancer
Lantheus Medical Imaging

An Adaptive Phase 2/3 Open-Label Multicenter Study to Assess the Diagnostic Performance of Piflufolastat F 18 PET/CT and Its Impact on Intended Clinical Management in Patients with Suspected, or at High Risk for, Metastatic Clear Cell Renal Cell Carcinoma.

Description:

This is an adaptive Phase 2/3, open-label, multi-center, single-arm study designed to evaluate diagnostic performance of piflufolastat F 18 PET/CT in the staging of patients suspected of having, or who are at high risk for, metastatic ccRCC and its impact on intended clinical management.

Sponsor:

Lantheus Medical Imaging

Phase:

Phase 2/3

Contacts:

Vicki White (Clinical Trial Lead)

clinicaltrials@lantheus.com

978-671-8886

Government Study Link:

NCT07084909 - Click here to see study on

ClinicalTrials.gov

Inclusion
  • ECOG 0-2 and life expectancy of at least 6 months
  • Completed staging evaluation with conventional imaging within 60 days prior to Study Day 1
  • Adults with ccRCC with at least 1 metastatic lesion (Ph 2) and suspected or high risk for metastatic disease (Ph 3)
Exclusion
  • Any unresolved active malignancy within past 3 years; any condition (e.g. dialysis) compromising safety/compliance
  • High energy (>300 KeV) gamma-emitting radioisotope within five (5) physical half-lives, prior to Day 1
  • Expected to receive anti-cancer treatment between baseline imaging, piflufolastat F 18 PET/CT, biopsy/surgery
  • Active systemic therapy prior to Day 1; 30-day (12 wks for immunotherapy) washout required from last therapy
  • Prior imaging with girentuximab or any PSMA-PET agent or any non-approved ccRCC imaging agent within the last 3-months

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Loading...